Literature DB >> 12478672

Neuroblastoma trends in Osaka, Japan, and Great Britain 1970-1994, in relation to screening.

Satoshi Honjo1, Helen E Doran, Charles A Stiller, Wakiko Ajiki, Hideaki Tsukuma, Akira Oshima, Michel P Coleman.   

Abstract

Japan pioneered and has maintained a nationwide mass screening programme for neuroblastoma since 1985 without prior evaluation among a target population. Convincing population-based evaluation of the ongoing programme has also been very limited because a population-based registry for childhood cancer has not been in operation. This report describes trends in incidence of and mortality from neuroblastoma in Osaka Prefecture, Japan, using Great Britain as an external control, between 1970 and 1994. Incidence and mortality rates were comparable between the 2 areas before the beginning of screening in Osaka. However, incidence rates were markedly increased in Osaka, especially among children younger than 1 year, from 25.9 per million children during 1970-1979 to 240.2 during 1991-1994, while age-standardized incidence rates for metastatic tumours among children aged 1 year or above did not decrease after introduction of the programme. Age-standardized mortality rates per million were unchanged at 3.9 (1970-1979) and 4.1 (1991-1994) in Osaka and 5.7 (1971-1979) and 5.0 (1991-1994) in Great Britain. Cumulative incidence rates among those up to 15 years old progressively increased from 103.4 per million (1970-1979) to 350.0 (1991-1994) in Osaka, though cumulative mortality rates did not decrease: 52.0 and 57.5, respectively. Corresponding figures in Great Britain were 101.0, 115.1, 78.6 and 70.1, respectively. The present findings show little beneficial effect of the screening programme. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12478672     DOI: 10.1002/ijc.10859

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Where medicine, business, and public policy intersect.

Authors:  Chantell L Wilson; Stephanie Schultz; Scott A Waldman
Journal:  Biotechnol Healthc       Date:  2007-02

2.  MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening.

Authors:  T Iehara; H Hosoi; K Akazawa; Y Matsumoto; K Yamamoto; S Suita; T Tajiri; T Kusafuka; E Hiyama; M Kaneko; F Sasaki; T Sugimoto; T Sawada
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

3.  Neuroblastoma Mass Screening--What Can We Learn From It?

Authors:  Kota Katanoda
Journal:  J Epidemiol       Date:  2016       Impact factor: 3.211

4.  Childhood cancer incidence and survival in Japan and England: A population-based study (1993-2010).

Authors:  Kayo Nakata; Yuri Ito; Winnie Magadi; Audrey Bonaventure; Charles A Stiller; Kota Katanoda; Tomohiro Matsuda; Isao Miyashiro; Kathy Pritchard-Jones; Bernard Rachet
Journal:  Cancer Sci       Date:  2017-12-26       Impact factor: 6.716

5.  Secular trends in neuroblastoma mortality before and after the cessation of national mass screening in Japan.

Authors:  Kota Katanoda; Kunihiko Hayashi; Keiko Yamamoto; Tomotaka Sobue
Journal:  J Epidemiol       Date:  2009-08-01       Impact factor: 3.211

6.  Effectiveness of nationwide screening program for neuroblastoma in Japan.

Authors:  Akinori Hisashige
Journal:  Glob J Health Sci       Date:  2014-04-10

7.  Effects of the Cessation of Mass Screening for Neuroblastoma at 6 Months of Age: A Population-Based Study in Osaka, Japan.

Authors:  Akiko Ioka; Masami Inoue; Akihiro Yoneda; Tetsuro Nakamura; Junichi Hara; Yoshiko Hashii; Naoki Sakata; Kazumi Yamato; Hideaki Tsukuma; Keisei Kawa
Journal:  J Epidemiol       Date:  2015-11-07       Impact factor: 3.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.